ClinicalTrials.Veeva

Menu

Comparing Mortality for Low vs High Peripheral Oxygen Saturation in COPD-patients With Acute Exacerbation (O2flow-COPD)

M

Modulex

Status and phase

Enrolling
Phase 4

Conditions

Chronic Obstructive Pulmonary Disease Exacerbation
COPD Exacerbation

Treatments

Drug: Oxygen gas

Study type

Interventional

Funder types

Other

Identifiers

NCT04223050
19/4298 (Registry Identifier)
2019-002498-80 (EudraCT Number)

Details and patient eligibility

About

Chronic obstructive pulmonary disease (COPD) is a common disorder that affects approximately 400,000 Danish citizens. About 3,000-3,500 Danes die yearly because of the disorder, and the costs associated with hospital admissions are estimated to be 535 million Danish kroner (DKK). Patients with COPD risk a worsening of their disorder, and in most cases, this will require hospitalization. One of the used treatments is providing oxygen to the patients via e.g. masks. The recommendations on oxygen treatment are currently based on a study from 2010 where 37% of the participants in this study did not receive the intended treatment, which may have had massive effects on the results. It is worrying that no other studies have shown which oxygen treatment is safest for the patients. As such, we deem it important to study how best to treat the patients.

Our study is of high clinical relevance as hospitals receive patients with worsening of COPD daily. We need more, better data regarding the oxygen treatment of our patients, in order to provide our patients with the best possible care. The purpose of our study is thus to determine which oxygen treatment is best for patients with acute worsening of COPD symptoms. We will use a prospective, randomized controlled open-label trial. We will use two treatments: Treatment 1 is giving oxygen to the patient to reach a peripheral oxygen saturation of above 94%. Treatment 2 is giving oxygen to reach a peripheral oxygen saturation of between 88% and 92%.

Our primary outcome is 30-day all-cause mortality, with secondary outcomes being 7-day all-cause mortality, need for non-invasive ventilation, intubation or intensive care admission, over-all length of hospital stay and respiratory acidosis.

We believe that a lower oxygen saturation percentage may be superior as one study (Austin et al., 2010) showed a lower mortality rate in the group of patients that had a lower peripheral oxygen saturation. Additionally, the risk of respiratory acidosis and hypercapnia were lower. We wish to perform our study in the hospital sector as this study was performed in the prehospital sector and thus their results cannot be translated directly.

Full description

Please refer to the full protocol.

Enrollment

415 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • age 18 years or older
  • ability to give informed consent
  • previously diagnosed COPD (either confirmed diagnosis at prior hospital - contact or from their general practitioner or confirmed diagnosis by the treating physician in the emergency department (verified by use of relevant medication))
  • admitted with acute exacerbation (acute and worsened shortness of breath) of COPD
  • requiring oxygen treatment

Exclusion criteria

  • Instability at arrival requiring immediate lifesaving treatment, e.g. intubation or non-invasive ventilation, within the first 30 minutes
  • Expected total length of stay in hospital < 12 hours
  • Planned transfer to another hospital within 12 hours
  • Unwilling to have repeated arterial blood gas analyses within the first 12 hours
  • Patients judged terminal by treating physician in the emergency department
  • Non-residents of the particular country
  • Expected impossible follow-up
  • Fertile women (<50 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG
  • Prior participation in the study

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

415 participants in 2 patient groups

High oxygen saturation
Active Comparator group
Description:
Peripheral oxygen saturation level \>94%
Treatment:
Drug: Oxygen gas
Low oxygen saturation
Active Comparator group
Description:
Peripheral oxygen saturation level 88-92%
Treatment:
Drug: Oxygen gas

Trial contacts and locations

4

Loading...

Central trial contact

Line E. Lilholm Laugesen, MScPH; Mikkel Brabrand, MD PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems